Objective: A systematic review on S-adenosylmethionine (SAMe) for treatment of
neuropsychiatric conditions and comorbid medical conditions. Data Sources: Searches were …

Background Depression is a recurrent illness with high rates of chronicity, treatment‐
resistance and significant economic impact. There is evidence in the literature that S …

Introduction‐S‐adenosyl‐l‐methionine (SAMe) is a naturally‐occurring substance which is a
major source of methyl groups in the brain. Material and methods‐We conducted a meta …

Despite the increasingly large array of antidepressants available to treat major depressive
disorder, patients continue to experience relatively modest response and remission rates. In …

Interest in nonpharmaceutical supplements for treating major depressive disorder (MDD)
has increased significantly, both among patients and among clinicians during the past …

Objective. To review the antidepressant efficacy of S-Adenosyl-L-Methionine (SAMe) both in
monotherapy and/or in augmentation with antidepressants to better understand its potential …

Mood disorders can be relatively straightforward or they can assume complex forms that are
difficult to treat. In this chapter, we review the epidemiology, diagnosis, comorbidity …

Abstract As many as 29% to 46% of patients with major depressive disorder (MDD) show
only partial or no response to an adequate course of an antidepressant. The current practice …

Abstract s-adenosyl-l-methionine (SAMe) is a natural substance which constitutes the most
important methyl donor in transmethylation reactions in the central nervous system. Several …

Mood disorders affect more than 500 million people around the world. In the last decade,
their prevalence has increased, and many people suffer from nervousness, anxiety, and …